Gibson Dunn Advises Coastlands Capital on up to $30 Million Financing for Longeveron Inc.
Firm News | March 10, 2026
Gibson Dunn represented Coastlands Capital as lead investor in the up to $30 million private placement financing for Longeveron Inc., a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions.
Gibson Dunn regularly advises life sciences investors on private placement financings for clinical-stage biotechnology companies.
The Gibson Dunn team included Ryan Murr, Branden Berns, and Jasmine Vitug.